COLchicine and non-enteric coated aspirin in the Cardiovascular Outcomes Trial of patients with Type 2 Diabetes (COLCOT-T2D)

Clinical trials
In Progress
Behaviours and Mental Disorders, Chronic Diseases, Heart and Blood Diseases, Heart Disease, Nutritional and Metabolic Diseases, Primary Care
November 2025 – December 2027 | Funders: Canadian Institutes of Health Research, Government of Quebec, Montreal Heart Institute Foundation | Partners: Montreal Heart Institute

About

COLCOT-TD2 Logo

The Montreal Heart Institute is currently conducting a large clinical trial, COLCOT-T2D, to determine whether an anti-inflammatory drug (colchicine) and an anti-platelet drug (aspirin), in combination or alone, can prevent cardiovascular events in patients with Type 2 diabetes who have never suffered a cardiovascular event.

Montreal Heart Institute Logo

Team Members

Contact Information